These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 36690204)

  • 41. Differentiating primary CNS lymphoma from glioblastoma multiforme: assessment using arterial spin labeling, diffusion-weighted imaging, and ¹⁸F-fluorodeoxyglucose positron emission tomography.
    Yamashita K; Yoshiura T; Hiwatashi A; Togao O; Yoshimoto K; Suzuki SO; Abe K; Kikuchi K; Maruoka Y; Mizoguchi M; Iwaki T; Honda H
    Neuroradiology; 2013 Feb; 55(2):135-43. PubMed ID: 22961074
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Differentiation of newly diagnosed glioblastoma multiforme and intracranial diffuse large B-cell Lymphoma using (11)C-methionine and (18)F-FDG PET.
    Okada Y; Nihashi T; Fujii M; Kato K; Okochi Y; Ando Y; Yamashita M; Maesawa S; Takebayashi S; Wakabayashi T; Naganawa S
    Clin Nucl Med; 2012 Sep; 37(9):843-9. PubMed ID: 22889772
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Primary central nervous system lymphoma and atypical glioblastoma: Differentiation using radiomics approach.
    Suh HB; Choi YS; Bae S; Ahn SS; Chang JH; Kang SG; Kim EH; Kim SH; Lee SK
    Eur Radiol; 2018 Sep; 28(9):3832-3839. PubMed ID: 29626238
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Imaging features (CT, MRI, MRS, and PET/CT) of primary central nervous system lymphoma in immunocompetent patients.
    Cheng G; Zhang J
    Neurol Sci; 2019 Mar; 40(3):535-542. PubMed ID: 30580380
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Usefulness of Serum Soluble Interleukin-2 Receptor Levels for Differentiating between PCNSL and SCNSL.
    Mitobe Y; Matsuda KI; Sonoda Y
    Neurol Med Chir (Tokyo); 2023 Mar; 63(3):111-115. PubMed ID: 36682790
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Diagnostic performance of DWI for differentiating primary central nervous system lymphoma from glioblastoma: a systematic review and meta-analysis.
    Lu X; Xu W; Wei Y; Li T; Gao L; Fu X; Yao Y; Wang L
    Neurol Sci; 2019 May; 40(5):947-956. PubMed ID: 30706241
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Role of intra-tumoral vasculature imaging features on susceptibility weighted imaging in differentiating primary central nervous system lymphoma from glioblastoma: a multiparametric comparison with pathological validation.
    Bhattacharjee R; Gupta M; Singh T; Sharma S; Khanna G; Parvaze SP; Patir R; Vaishya S; Ahlawat S; Singh A; Gupta RK
    Neuroradiology; 2022 Sep; 64(9):1801-1818. PubMed ID: 35435463
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Primary central nervous system lymphoma and glioblastoma: differentiation using dynamic susceptibility-contrast perfusion-weighted imaging, diffusion-weighted imaging, and (18)F-fluorodeoxyglucose positron emission tomography.
    Nakajima S; Okada T; Yamamoto A; Kanagaki M; Fushimi Y; Okada T; Arakawa Y; Takagi Y; Miyamoto S; Togashi K
    Clin Imaging; 2015; 39(3):390-5. PubMed ID: 25547624
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The utility of body FDG PET in staging primary central nervous system lymphoma.
    Mohile NA; Deangelis LM; Abrey LE
    Neuro Oncol; 2008 Apr; 10(2):223-8. PubMed ID: 18287338
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Radiomics features to distinguish glioblastoma from primary central nervous system lymphoma on multi-parametric MRI.
    Kim Y; Cho HH; Kim ST; Park H; Nam D; Kong DS
    Neuroradiology; 2018 Dec; 60(12):1297-1305. PubMed ID: 30232517
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Use of FDG-PET/CT for systemic assessment of suspected primary central nervous system lymphoma: a LOC study.
    Bertaux M; Houillier C; Edeline V; Habert MO; Mokhtari K; Giron A; Bergeret S; Hoang-Xuan K; Cassoux N; Touitou V; Choquet S; Soussain C; Kas A
    J Neurooncol; 2020 Jun; 148(2):343-352. PubMed ID: 32405997
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Primary Central Nervous System Lymphoma: Diagnostic Yield of Whole-Body CT and FDG PET/CT for Initial Systemic Imaging.
    Suh CH; Kim HS; Park JE; Jung SC; Choi CG; Kim SJ
    Radiology; 2019 Aug; 292(2):440-446. PubMed ID: 31237497
    [TBL] [Abstract][Full Text] [Related]  

  • 53. ¹⁸F-Fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant gliomas.
    Hirata K; Terasaka S; Shiga T; Hattori N; Magota K; Kobayashi H; Yamaguchi S; Houkin K; Tanaka S; Kuge Y; Tamaki N
    Eur J Nucl Med Mol Imaging; 2012 May; 39(5):760-70. PubMed ID: 22307533
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Diagnostic delay and prognosis in primary central nervous system lymphoma compared with glioblastoma multiforme.
    Cerqua R; Balestrini S; Perozzi C; Cameriere V; Renzi S; Lagalla G; Mancini G; Montanari M; Leoni P; Scerrati M; Iacoangeli M; Silvestrini M; Luzzi S; Provinciali L
    Neurol Sci; 2016 Jan; 37(1):23-29. PubMed ID: 26233232
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Radiological features of cerebellar glioblastoma.
    Kikuchi K; Hiratsuka Y; Kohno S; Ohue S; Miki H; Mochizuki T
    J Neuroradiol; 2016 Jul; 43(4):260-5. PubMed ID: 26740386
    [TBL] [Abstract][Full Text] [Related]  

  • 56. LCK expression is a potential biomarker for distinguishing primary central nervous system lymphoma from glioblastoma multiforme.
    Ge L; Xu L; Lu S; Yan H
    FEBS Open Bio; 2020 May; 10(5):904-911. PubMed ID: 32237064
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Deep Learning for Automatic Differential Diagnosis of Primary Central Nervous System Lymphoma and Glioblastoma: Multi-Parametric Magnetic Resonance Imaging Based Convolutional Neural Network Model.
    Xia W; Hu B; Li H; Shi W; Tang Y; Yu Y; Geng C; Wu Q; Yang L; Yu Z; Geng D; Li Y
    J Magn Reson Imaging; 2021 Sep; 54(3):880-887. PubMed ID: 33694250
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hemorrhagic Attitude in Frameless and Frame-Based Stereotactic Biopsy for Deep-Seated Primary Central Nervous System Lymphomas in Immunocompetent Patients: A Multicentric Analysis of the Last Twenty Years.
    Callovini GM; Sherkat S; Sperduti I; Crispo F; Raus L; Gazzeri R; Telera S
    World Neurosurg; 2021 May; 149():e1017-e1025. PubMed ID: 33476784
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combined use of 18 F-FDG PET and corticosteroid for diagnosis of deep-seated primary central nervous system lymphoma without histopathological confirmation.
    Yamaguchi S; Hirata K; Kaneko S; Kobayashi H; Shiga T; Kobayashi K; Onimaru R; Shirato H; Tamaki N; Terasaka S; Houkin K
    Acta Neurochir (Wien); 2015 Feb; 157(2):187-94. PubMed ID: 25488176
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tumor hypoxia and microscopic diffusion capacity in brain tumors: a comparison of (62)Cu-Diacetyl-Bis (N4-Methylthiosemicarbazone) PET/CT and diffusion-weighted MR imaging.
    Hino-Shishikura A; Tateishi U; Shibata H; Yoneyama T; Nishii T; Torii I; Tateishi K; Ohtake M; Kawahara N; Inoue T
    Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1419-27. PubMed ID: 24719157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.